These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. Beerli RR; Hell T; Merkel AS; Grawunder U PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162 [TBL] [Abstract][Full Text] [Related]
5. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300 [TBL] [Abstract][Full Text] [Related]
6. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation. Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201 [TBL] [Abstract][Full Text] [Related]
7. Curative properties of noninternalizing antibody-drug conjugates based on maytansinoids. Perrino E; Steiner M; Krall N; Bernardes GJ; Pretto F; Casi G; Neri D Cancer Res; 2014 May; 74(9):2569-78. PubMed ID: 24520075 [TBL] [Abstract][Full Text] [Related]
8. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424 [TBL] [Abstract][Full Text] [Related]
9. A New Triglycyl Peptide Linker for Antibody-Drug Conjugates (ADCs) with Improved Targeted Killing of Cancer Cells. Singh R; Setiady YY; Ponte J; Kovtun YV; Lai KC; Hong EE; Fishkin N; Dong L; Jones GE; Coccia JA; Lanieri L; Veale K; Costoplus JA; Skaletskaya A; Gabriel R; Salomon P; Wu R; Qiu Q; Erickson HK; Lambert JM; Chari RV; Widdison WC Mol Cancer Ther; 2016 Jun; 15(6):1311-20. PubMed ID: 27197308 [TBL] [Abstract][Full Text] [Related]
10. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates. Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844 [TBL] [Abstract][Full Text] [Related]
12. Semisynthetic maytansine analogues for the targeted treatment of cancer. Widdison WC; Wilhelm SD; Cavanagh EE; Whiteman KR; Leece BA; Kovtun Y; Goldmacher VS; Xie H; Steeves RM; Lutz RJ; Zhao R; Wang L; Blättler WA; Chari RV J Med Chem; 2006 Jul; 49(14):4392-408. PubMed ID: 16821799 [TBL] [Abstract][Full Text] [Related]
13. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Erickson HK; Park PU; Widdison WC; Kovtun YV; Garrett LM; Hoffman K; Lutz RJ; Goldmacher VS; Blättler WA Cancer Res; 2006 Apr; 66(8):4426-33. PubMed ID: 16618769 [TBL] [Abstract][Full Text] [Related]
14. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Kovtun YV; Audette CA; Mayo MF; Jones GE; Doherty H; Maloney EK; Erickson HK; Sun X; Wilhelm S; Ab O; Lai KC; Widdison WC; Kellogg B; Johnson H; Pinkas J; Lutz RJ; Singh R; Goldmacher VS; Chari RV Cancer Res; 2010 Mar; 70(6):2528-37. PubMed ID: 20197459 [TBL] [Abstract][Full Text] [Related]
15. MEN1309/OBT076, a First-In-Class Antibody-Drug Conjugate Targeting CD205 in Solid Tumors. Merlino G; Fiascarelli A; Bigioni M; Bressan A; Carrisi C; Bellarosa D; Salerno M; Bugianesi R; Manno R; Bernadó Morales C; Arribas J; Dusek RL; Ackroyd JE; Pham PH; Awdew R; Aud D; Trang M; Lynch CM; Terrett J; Wilson KE; Rohlff C; Manzini S; Pellacani A; Binaschi M Mol Cancer Ther; 2019 Sep; 18(9):1533-1543. PubMed ID: 31227646 [TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Polson AG; Calemine-Fenaux J; Chan P; Chang W; Christensen E; Clark S; de Sauvage FJ; Eaton D; Elkins K; Elliott JM; Frantz G; Fuji RN; Gray A; Harden K; Ingle GS; Kljavin NM; Koeppen H; Nelson C; Prabhu S; Raab H; Ross S; Slaga DS; Stephan JP; Scales SJ; Spencer SD; Vandlen R; Wranik B; Yu SF; Zheng B; Ebens A Cancer Res; 2009 Mar; 69(6):2358-64. PubMed ID: 19258515 [TBL] [Abstract][Full Text] [Related]
17. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Kellogg BA; Garrett L; Kovtun Y; Lai KC; Leece B; Miller M; Payne G; Steeves R; Whiteman KR; Widdison W; Xie H; Singh R; Chari RV; Lambert JM; Lutz RJ Bioconjug Chem; 2011 Apr; 22(4):717-27. PubMed ID: 21425776 [TBL] [Abstract][Full Text] [Related]
18. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload. Wang Y; Fan S; Zhong W; Zhou X; Li S Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157 [TBL] [Abstract][Full Text] [Related]
19. Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering. Pillow TH; Tien J; Parsons-Reponte KL; Bhakta S; Li H; Staben LR; Li G; Chuh J; Fourie-O'Donohue A; Darwish M; Yip V; Liu L; Leipold DD; Su D; Wu E; Spencer SD; Shen BQ; Xu K; Kozak KR; Raab H; Vandlen R; Lewis Phillips GD; Scheller RH; Polakis P; Sliwkowski MX; Flygare JA; Junutula JR J Med Chem; 2014 Oct; 57(19):7890-9. PubMed ID: 25191794 [TBL] [Abstract][Full Text] [Related]
20. Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors. Decary S; Berne PF; Nicolazzi C; Lefebvre AM; Dabdoubi T; Cameron B; Rival P; Devaud C; Prades C; Bouchard H; Cassé A; Henry C; Amara C; Brillac C; Ferrari P; Maçon L; Lacoste E; Combeau C; Beys E; Naimi S; García-Echeverría C; Mayaux JF; Blanc V Clin Cancer Res; 2020 Dec; 26(24):6589-6599. PubMed ID: 33046521 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]